Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Common Stock (NQ:TVGN)

1.190 +0.100 (+9.19%)
Streaming Delayed Price Updated: 2:46 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 999,776
Open 1.110
Bid (Size) 1.190 (31)
Ask (Size) 1.200 (1,034)
Prev. Close 1.090
Today's Range 1.110 - 1.200
52wk Range 0.2556 - 3.090
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
From Tevogen Bio Inc
Via GlobeNewswire

Performance

YTD
+12.3%
+12.3%
1 Month
+10.2%
+10.2%
3 Month
-23.2%
-23.2%
6 Month
-14.4%
-14.4%
1 Year
+19.0%
+19.0%

More News

Read More
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
From Tevogen Bio Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Monday?
Via Chartmill
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On?
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Announces 2025 Annual Meeting
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential
Via Benzinga
This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
From Tevogen Bio Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tevogen Bio Holdings Inc. - Common Stock publicly traded?
Yes, Tevogen Bio Holdings Inc. - Common Stock is publicly traded.
What exchange does Tevogen Bio Holdings Inc. - Common Stock trade on?
Tevogen Bio Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tevogen Bio Holdings Inc. - Common Stock?
The ticker symbol for Tevogen Bio Holdings Inc. - Common Stock is TVGN on the Nasdaq Stock Market
What is the current price of Tevogen Bio Holdings Inc. - Common Stock?
The current price of Tevogen Bio Holdings Inc. - Common Stock is 1.190
When was Tevogen Bio Holdings Inc. - Common Stock last traded?
The last trade of Tevogen Bio Holdings Inc. - Common Stock was at 05/12/25 02:46 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.